HDAC inhibitors have been proven to be effective in several pre-clinical models of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, psoriasis and ulcerative colitis [162]. Here, HDAC9 is linked to rheumatoid arthritis.